18F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes

Anjos, Dalton Alexandre dos; Habr‐Gama, Angelita; Vailati, Bruna Borba; Rossi, C.; Coturel, Adelina E.; Perez, Rodrigo Oliva; Julião, Guilherme P. São; Sousa, João Batista de; Buchpiguel, Carlos Alberto

doi:10.1007/s12149-016-1089-4

Cited by 17 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, as the patients could receive adjuvant chemotherapy according to the postoperative tumour stage after curative resection of the primary tumour, we tried to make up for the limitations of our study by excluding patients with stage IV cancer from the study 30 . In addition, a previous study by Dos Anjos et al 31 demonstrated that there was a signi cant difference in MTV and TLG, although there was no signi cant difference in SUVmax between mucinous and non-mucinous histological subtypes. This could be explained by the fact that histologic subtypes, such as mucinous or signet-ring cell adenocarcinoma, have characteristic features, such as pools of extracellular mucin, and are more likely to reach a higher pT stage than classical adenocarcinoma 3,9,32 .…”

Section: Discussionmentioning

confidence: 84%

Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma

Choi

Kang

Bae

et al. 2021

Preprint

View full text Add to dashboard Cite

We aimed to investigate the prognostic value of the metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in classical rectal adenocarcinoma (CRAC). We retrospectively reviewed 149 patients with CRAC who underwent preoperative 18F-FDG PET/CT at initial diagnosis followed by curative surgical resection. 18F-FDG PET/CT metabolic parameters including maximum standardized uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) for disease-free survival (DFS) and overall survival (OS) were evaluated for prognostic significance by univariate and multivariate analyses, along with conventional risk factors including pathologic T (pT) stage, lymph node (LN) metastasis, lymphovascular invasion (LVI), perineural invasion (PNI), and preoperative carcinoembryonic antigen (CEA) level. On univariate analysis, high pT stage, positive LN metastasis, LVI, PNI, MTV, and TLG were significant prognostic factors affecting DFS (all P < 0.05), while CEA level, high pT stage, positive LN metastasis, LVI, PNI, MTV, and TLG affected OS (all P < 0.05). On multivariate analysis, positive LN metastasis, LVI, MTV, and TLG were independent prognostic factors affecting DFS (all P < 0.05), while CEA level, positive LN metastasis, and MTV affected OS (all P < 0.05). Thus, MTV and TLG are independent prognostic factors for DFS and OS in CRAC patients.

show abstract

Section: Discussionmentioning

confidence: 84%

Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma

Choi

Kang

Bae

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…For the detection of residual cancer tissue, PET-CT findings present sensitivity of 93% and specificity of 53% and overall accuracy of 85% [3]. The accuracy of PET-CT in the prediction of cCR reaches 96% if it is combined with clinical evaluation [48].…”

Section: Positron Emission Tomography/computed Tomography (Pet/ct)mentioning

confidence: 99%

“…Considering the fact that a metabolic CR is not equivalent to pCR in all cases, several aspects are being assessed to increase the value of PET-CT (e.g., the metabolic tumor volume; the total lesion glycolysis (TLG) and change of its percentage; a reduction in the maximal SUV by applying variable interval periods) [7,48].…”

Section: Positron Emission Tomography/computed Tomography (Pet/ct)mentioning

confidence: 99%

Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy

Kokaine

Gardovskis

2021

Medicina

View full text Add to dashboard Cite

The response to neoadjuvant chemoradiation therapy is an important prognostic factor for locally advanced rectal cancer. Although the majority of the patients after neoadjuvant therapy are referred to following surgery, the clinical data show that complete clinical or pathological response is found in a significant proportion of the patients. Diagnostic accuracy of confirming the complete response has a crucial role in further management of a rectal cancer patient. As the rate of clinical complete response, unfortunately, is not always consistent with pathological complete response, accurate diagnostic parameters and predictive markers of tumor response may help to guide more personalized treatment strategies and identify potential candidates for nonoperative management more safely. The management of complete response demands interdisciplinary collaboration including oncologists, radiotherapists, radiologists, pathologists, endoscopists and surgeons, because the absence of a multidisciplinary approach may compromise the oncological outcome. Prediction and improvement of rectal cancer response to neoadjuvant therapy is still an active and challenging field of further research. This literature review is summarizing the main, currently known clinical information about the complete response that could be useful in case if encountering such condition in rectal cancer patients after neoadjuvant chemoradiation therapy, using as a source PubMed publications from 2010–2021 matching the search terms “rectal cancer”, “neoadjuvant therapy” and “response”.

show abstract

“…The use of fluoro-2-deoxy-D-glucose (FDG) allows for the estimate of tissue metabolism (standard uptake values [SUV]) within areas of interest, and fused images of PET and CT may indicate precise anatomical areas of residual cancer cells, even among mucinous histological subtypes. 54 Most of the available studies have focused on SUV variation for the identification of complete responders to nCRT using variable interval periods and sequential PET/CT imaging. 22,55,56 Accuracies, however, have been insufficient for its routine recommendation into clinical practice.…”

Section: Radiological Assessmentmentioning

confidence: 99%

Management of the Complete Clinical Response

Habr‐Gama¹,

Julião²,

Vailati³

et al. 2017

Clinics in Colon and Rectal Surgery

Self Cite

View full text Add to dashboard Cite

Organ preservation is considered in the management of selected patients with rectal cancer. Complete clinical response observed after neoadjuvant chemoradiation for rectal cancer is one of these cases. Patients who present complete clinical response are candidates to the watch-and-wait approach, when radical surgery is not immediately performed and is offered only to patients in the event of a local relapse. These patients are included in a strict follow-up, and up of 70% of them will never be operated during the follow-up. This strategy is associated with similar oncological outcomes as patients operated on, and the advantage of avoiding the morbidity associated to the radical operation. In this article we will discuss in detail the best candidates for this approach, the protocol itself, and the long-term outcomes.

show abstract

18F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes

Abstract: Metabolic parameters at baseline PET/CT for patients with rectal cancer are similar in mucinous and nonmucinous histological subtypes.

Cited by 17 publications

References 14 publications

Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma

Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma

Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy

Management of the Complete Clinical Response

Contact Info

Product

Resources

About